 The stock of Acadia Pharmaceuticals NASDAQ: ACAD, a biopharmaceutical company focused on neuroscience drugs, has seen a rise of 26 over the last month. ACAD stock rose from levels of around 19 in early December to levels of 27 on December 20, before cooling off to levels of 24 currently. 